The angiotensin II type 1 receptor-neprilysin inhibitor LCZ696 blocked aldosterone synthesis in a human adrenocortical cell line

Hypertension Research

Volumn 39, Issue 11, 2016, Pages 758-763

  Miura, Shin Ichiro ^a   Suematsu, Yasunori ^a   Matsuo, Yoshino ^a   Tomita, Sayo ^a   Nakayama, Asuka ^a   Goto, Masaki ^a   Arimura, Tadaaki ^a   Kuwano, Takashi ^a   Yahiro, Eiji ^a   Saku, Keijiro ^a  

^a FUKUOKA UNIVERSITY   (Japan)

Author keywords

aldosterone; atrial natriuretic peptide; brain natriuretic peptide; neprilysin inhibition

Indexed keywords

3 (1 BIPHENYL 4 YLMETHYL 3 CARBOXY 1 BUTYLCARBAMOYL)PROPIONIC ACID; 3(OR 17)BETA HYDROXYSTEROID DEHYDROGENASE; ALDOSTERONE; ANGIOTENSIN 1 RECEPTOR; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; CYCLIC GMP DEPENDENT PROTEIN KINASE; MEMBRANE METALLOENDOPEPTIDASE; MESSENGER RNA; RENIN; RGS PROTEIN; SACUBITRIL PLUS VALSARTAN; VALSARTAN; AMINOBUTYRIC ACID DERIVATIVE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; TETRAZOLE DERIVATIVE;

ADRENAL CORTEX CELL; ARTICLE; BINDING AFFINITY; BINDING COMPETITION; CELL LINE; CLINICAL STUDY; CONTROLLED STUDY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; EMBRYO; ENZYME INHIBITION; EVOKED RESPONSE; HEK293 CELL LINE; HUMAN; HUMAN CELL; NONHUMAN; SIGNAL TRANSDUCTION; ADRENAL CORTEX; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CYTOLOGY; DRUG EFFECTS; METABOLISM;

ADRENAL CORTEX; ALDOSTERONE; AMINOBUTYRATES; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN RECEPTOR ANTAGONISTS; CELL LINE; HUMANS; NEPRILYSIN; RECEPTOR, ANGIOTENSIN, TYPE 1; TETRAZOLES; VALSARTAN;

EID: 84994711469     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2016.72     Document Type: Article

References (24)

1. Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, Ostergren J, Pfeffer MA, Swedberg KCHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARMAlternative trial. Lancet 2003; 362: 772e6
2. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996; 334: 1349-1355
3. Solomon SD, Zile M, Pieske B, Voors A, Shah A, Kraigher-Krainer E, Shi V, Bransford T, Takeuchi M, Gong J, Lefkowitz M, Packer M, McMurray JJ. Prospective comparison of ARNI with ARB on Management Of heart failUre with preserved ejectioN fraction (PARAMOUNT) Investigators. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet 2012; 380: 1387-1395
4. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MRPARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition vs. enalapril in heart failure. N Engl J Med 2014; 371: 993-1004
5. Ito S, Satoh M, Tamaki Y, Gotou H, Charney A, Okino N, Akahori M, Zhang J. Safety and efficacy of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Japanese patients with hypertension and renal dysfunction. Hypertens Res 2015; 38: 269-275
6. Suematsu Y, Miura S, Goto M, Matsuo Y, Arimura T, Kuwano T, Imaizumi S, Iwata A, Yahiro E, Saku K. LCZ696, an angiotensin-receptor neprilysin inhibitor, improves cardiac function with the attenuation of fibrosis in heart failure with reduced ejection fraction in streptozotocin-induced diabetic mice. Eur J Heart Fail 2016; 18: 386-393
7. Potter LR. Natriuretic peptide metabolism, clearance and degradation. FEBS J 2011; 278: 1808e17
8. Dell?Italia LJ. Translational success stories: angiotensin receptor 1 antagonists in heart failure. Circ Res 2011; 109: 437e52
9. He BJ, Anderson ME. Aldosterone and cardiovascular disease: the heart of the matter. Trends Endocrinol Metab 2013; 24: 21e30
10. Mulè G, Nardi E, Guarino L, Cacciatore V, Geraci G, Calcaterra I, Oddo B, Vaccaro F, Cottone S. Plasma aldosterone and its relationship with left ventricular mass in hypertensive patients with early-stage chronic kidney disease. Hypertens Res 2015; 38: 276-283
11. Cuspidi C, Tadic M, Sala C. Aldosterone and abnormal left ventricular geometry in chronic kidney disease. Hypertens Res 2015; 38: 314-316
12. Miura S, Nakayama A, Tomita S, Matsuo Y, Suematsu Y, Saku K. Comparison of aldosterone synthesis in adrenal cells, effect of various AT1 receptor blockers with or without atrial natriuretic peptide. Clin Exp Hypertens 2015; 37: 353-357
13. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt BEMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011; 364: 11-21
14. Ishida J, Asada S, Daitoku H, Fujiwara K, Kon Y, Sugaya T, Murakami K, Nakajima T, Kasuya Y, Fukamizu A. Expression and characterization of mouse angiotensin II type 1a receptor tagging hemagglutinin epitope in cultured cell. Int J Mol Med 1999; 3: 263-270
15. Ota T, Doi M, Yamazaki F, Yarimizu D, Okada K, Murai I, Hayashi H, Kunisue S, Nakagawa Y, Okamura H. Angiotensin II triggers expression of the adrenal gland zona glomerulosa-specific 3β-hydroxysteroid dehydrogenase isoenzyme through de novo protein synthesis of the orphan nuclear receptors NGFIB and NURR1. Mol Cell Biol 2014; 34: 3880-3894
16. Sonnenberg JL, Sakane Y, Jeng AY, Koehn JA, Ansell JA, Wennogle LP, Ghai RD. Identification of protease 3.4.24.11 as the major atrial natriuretic factor degrading enzyme in the rat kidney. Peptides 1988; 9: 173-180
17. Massien C, Azizi M, Guyene TT, Vesterqvist O, Mangold B, Menard J. Pharmacodynamic effects of dual neutral endopeptidase angiotensin-converting enzyme inhibition vs. angiotensin converting enzyme inhibition in humans. Clin Pharmacol Ther 1999; 65: 448-459
18. Gu J, Noe A, Chandra P, Al-Fayoumi S, Ligueros-Saylan M, Sarangapani R, Maahs S, Ksander G, Rigel DF, Jeng AY, Lin TH, Zheng W, Dole WP. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-Acting angiotensin receptor-neprilysin inhibitor (ARNi). J Clin Pharmacol 2010; 50: 401-414
19. Stephenson SL, Kenny AJ. Metabolism of neuropeptides. Hydrolysis of the angiotensins, bradykinin, substance P and oxytocin by pig kidney microvillar membranes. Biochem J 1987; 241: 237-247
20. Ferro CJ, Spratt JC, Haynes WG, Webb DJ. Inhibition of neutral endopeptidase causes vasoconstriction of human resistance vessels in vivo. Circulation 1998; 97: 2323-2330
21. Tokudome T, Kishimoto I, Horio T, Arai Y, Schwenke DO, Hino J, Okano I, Kawano Y, Kohno M, Miyazato M, Nakao K, Kangawa K. Regulator of G-protein signaling subtype 4 mediates antihypertrophic effect of locally secreted natriuretic peptides in the heart. Circulation 2008; 117: 2329-2339
22. Campbell WB, Currie MG, Needleman P. Inhibition of aldosterone biosynthesis by atriopeptins in rat adrenal cells. Circ Res 1985; 57: 113-118
23. Olson LJ, Ho BY, Cashdollar LW, Drewett JG. Functionally active catalytic domain is essential for guanylyl cyclase-linked receptor mediated inhibition of human aldosterone synthesis. Mol Pharmacol 1998; 54: 761-769
24. McDowell G, Coutie W, Shaw C, Buchanan KD, Struthers AD, Nicholls DP. The effect of the neutral endopeptidase inhibitor drug, candoxatril, on circulating levels of two of the most potent vasoactive peptides. Br J Clin Pharmacol 1997; 43: 329-332